Drug intelligence / Profile preview

SynB1 ELP2-DOXO

Development stage: Preclinical
Lead developer: University of Mississippi Medical Center
Modality: Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

SynB1 ELP2-DOXO is a research-stage biopolymer-drug conjugate designed as a thermally non-responsive control variant of the thermoresponsive conjugate SynB1 ELP1-DOXO. It is composed of three functional components: a cell-penetrating peptide (SynB1) to promote cellular and tumor uptake; an elastin-like polypeptide (ELP2) carrier; and the (6-maleimidocaproyl) hydrazone derivative of doxorubicin (DOXO-EMCH) as the active chemotherapeutic payload, linked via a pH-sensitive hydrazone bond. Under physiological conditions, the ELP2 carrier remains soluble and does not undergo phase transition (which occurs only above 60°C), making it effectively non-thermoresponsive. It has been evaluated in preclinical academic research, specifically in MDA-MB-231 triple-negative human breast cancer xenograft mouse models, to validate the thermal-targeting mechanism of its thermoresponsive counterpart.

Other names: SynB1 ELP2-DoxSynB-1 ELP2-DoxSynB 1 ELP2-DoxSynB1-ELP2-DOXOSynB-1-ELP2-DOXOSynB 1-ELP2-DOXOSynB1-ELP2-DoxSynB-1-ELP2-DoxSynB 1-ELP2-Dox

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on SynB1 ELP2-DOXO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynB1 ELP2-DOXO.

Explore the full profile